-
Je něco špatně v tomto záznamu ?
Operability assessment in CTEPH: Lessons from the CHEST-1 study
DP. Jenkins, A. Biederman, AM. D'Armini, PG. Dartevelle, HL. Gan, W. Klepetko, J. Lindner, E. Mayer, MM. Madani,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem, komentáře
- MeSH
- chronická nemoc MeSH
- embolektomie MeSH
- endarterektomie MeSH
- funkce pravé komory srdeční MeSH
- lidé MeSH
- plicní embolie * MeSH
- plicní hypertenze chirurgie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- komentáře MeSH
- práce podpořená grantem MeSH
Pulmonary endarterectomy is the gold standard treatment for chronic thromboembolic pulmonary hypertension and is potentially curative, although some patients are unsuitable for pulmonary endarterectomy and require alternative management. Lack of standardized assessment of pulmonary endarterectomy eligibility risks suboptimal treatment in some patients. We discuss the implications for future clinical trials and practice of a unique operability assessment in patients who have chronic thromboembolic pulmonary hypertension and were initially screened for inclusion in the CHEST-1 (Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase Stimulator Trial-1) study. The CHEST-1 study evaluated riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent/recurrent pulmonary hypertension after pulmonary endarterectomy. Screened patients who were initially considered "inoperable" underwent central independent adjudication by a committee of experienced surgeons, or local adjudication in collaboration with an experienced surgeon. Operability decisions were based on accessibility of thrombi and the association between pulmonary vascular resistance (PVR) and the extent of obstruction, using pulmonary angiography/computed tomography with ventilation/perfusion scintigraphy as the minimum diagnostic tests. Of 446 patients screened for CHEST-1, a total of 188 and 124 underwent central and local adjudication, respectively, after being initially considered to be "inoperable." After a second assessment by an experienced surgeon, 69 of these 312 "inoperable" patients were deemed operable. Rigorous measures in CHEST-1 guaranteed that only technically inoperable patients, or patients who had persistent/recurrent pulmonary hypertension, were enrolled, thus ensuring that only patients for whom surgery was not an option were enrolled. This study design sets new standards for future clinical trials and practice in CTEPH, helping to ensure that patients who have CTEPH receive optimal treatment.
Department of Cardiac Surgery Allenort Hospital Warsaw Poland
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19045617
- 003
- CZ-PrNML
- 005
- 20200605141844.0
- 007
- ta
- 008
- 200109s2016 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jtcvs.2016.02.062 $2 doi
- 035 __
- $a (PubMed)27083940
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Jenkins, David P $u National Pulmonary Endarterectomy Service, Department of Cardiothoracic Surgery, Papworth Hospital, Cambridge, United Kingdom. Electronic address: david.jenkins@papworth.nhs.uk.
- 245 10
- $a Operability assessment in CTEPH: Lessons from the CHEST-1 study / $c DP. Jenkins, A. Biederman, AM. D'Armini, PG. Dartevelle, HL. Gan, W. Klepetko, J. Lindner, E. Mayer, MM. Madani,
- 520 9_
- $a Pulmonary endarterectomy is the gold standard treatment for chronic thromboembolic pulmonary hypertension and is potentially curative, although some patients are unsuitable for pulmonary endarterectomy and require alternative management. Lack of standardized assessment of pulmonary endarterectomy eligibility risks suboptimal treatment in some patients. We discuss the implications for future clinical trials and practice of a unique operability assessment in patients who have chronic thromboembolic pulmonary hypertension and were initially screened for inclusion in the CHEST-1 (Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase Stimulator Trial-1) study. The CHEST-1 study evaluated riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent/recurrent pulmonary hypertension after pulmonary endarterectomy. Screened patients who were initially considered "inoperable" underwent central independent adjudication by a committee of experienced surgeons, or local adjudication in collaboration with an experienced surgeon. Operability decisions were based on accessibility of thrombi and the association between pulmonary vascular resistance (PVR) and the extent of obstruction, using pulmonary angiography/computed tomography with ventilation/perfusion scintigraphy as the minimum diagnostic tests. Of 446 patients screened for CHEST-1, a total of 188 and 124 underwent central and local adjudication, respectively, after being initially considered to be "inoperable." After a second assessment by an experienced surgeon, 69 of these 312 "inoperable" patients were deemed operable. Rigorous measures in CHEST-1 guaranteed that only technically inoperable patients, or patients who had persistent/recurrent pulmonary hypertension, were enrolled, thus ensuring that only patients for whom surgery was not an option were enrolled. This study design sets new standards for future clinical trials and practice in CTEPH, helping to ensure that patients who have CTEPH receive optimal treatment.
- 650 _2
- $a chronická nemoc $7 D002908
- 650 _2
- $a embolektomie $7 D017128
- 650 _2
- $a endarterektomie $7 D004691
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a plicní hypertenze $x chirurgie $7 D006976
- 650 12
- $a plicní embolie $7 D011655
- 650 _2
- $a funkce pravé komory srdeční $7 D016278
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a komentáře $7 D016420
- 700 1_
- $a Biederman, Andrzej $u Department of Cardiac Surgery, Allenort Hospital, Warsaw, Poland.
- 700 1_
- $a D'Armini, Andrea M $u Division of Cardiothoracic Surgery, Foundation "I.R.C.C.S. Policlinico San Matteo," University of Pavia School of Medicine, Pavia, Italy.
- 700 1_
- $a Dartevelle, Philippe G $u Department of Thoracic and Vascular Surgery and Heart Lung Transplantation, Marie-Lannelongue Hospital, Paris-Sud University, Le Plessis-Robinson, France.
- 700 1_
- $a Gan, Hui-Li $u Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, and Blood Vessel Disease, Beijing, China.
- 700 1_
- $a Klepetko, Walter $u Department of Cardiothoracic Surgery, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
- 700 1_
- $a Lindner, Jaroslav $u 2nd Surgical Department-Clinical Department of Cardiovascular Surgery, First Faculty of Medicine and General Teaching Hospital, Charles University Prague, Prague, Czech Republic.
- 700 1_
- $a Mayer, Eckhard $u Kerckhoff Heart and Lung Center, Bad Nauheim, Germany.
- 700 1_
- $a Madani, Michael M $u Division of Cardiovascular and Thoracic Surgery, University of California San Diego Medical Center, San Diego, Calif.
- 773 0_
- $w MED00003020 $t The Journal of thoracic and cardiovascular surgery $x 1097-685X $g Roč. 152, č. 3 (2016), s. 669-674.e3
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27083940 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200109 $b ABA008
- 991 __
- $a 20200605141843 $b ABA008
- 999 __
- $a ok $b bmc $g 1483885 $s 1084290
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 152 $c 3 $d 669-674.e3 $e 20160310 $i 1097-685X $m Journal of thoracic and cardiovascular surgery $n J Thorac Cardiovasc Surg $x MED00003020
- LZP __
- $a Pubmed-20200109
